Retatrutide research: five trials, three receptor targets, one compound.

The short version

Retatrutide is an investigational obesity and diabetes drug that is not approved anywhere as of 2026. It works by activating three hormone receptors at once — GIP, GLP-1, and glucagon — using a single injected molecule. Phase 2 clinical trials have produced the largest weight-loss numbers ever reported in a randomized drug trial: up to 24.2% of body weight at 48 weeks. A Phase 3 program (TRIUMPH) is now underway, and the first Phase 3 result was published in 2026.

This page summarizes the full published Retatrutide research record in order: how the molecule was engineered and how it works, what Phase 1b showed about its pharmacokinetics, what Phase 2 found in obesity and diabetes, what the liver-disease substudy found, and where the Phase 3 program stands. All numbers are cited to the study that produced them.

Mechanism: triple-receptor agonism

Retatrutide (LY3437943) is a 39-amino-acid synthetic peptide engineered to activate three class-B GPCRs (G protein-coupled receptors — cell-surface proteins that relay hormone signals into the cell) simultaneously: the GLP-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR).

Cryo-EM structures resolved the binding geometry at all three receptors. Retatrutide is approximately 8.9 times more potent at GIPR than native GIP, and 0.3× to 0.4× at GCGR and GLP-1R compared to their endogenous hormones ^[3]. The design amplifies the GIPR arm (which drives insulinotropic and adipose effects) while tempering the glucagon arm (to limit hyperglycemia) — a deliberate pharmacodynamic trade-off.

The GLP-1R component suppresses appetite and slows gastric emptying. The GIPR component augments glucose-dependent insulin secretion and influences adipose metabolism. The GCGR component increases energy expenditure through hepatic lipid metabolism and thermogenesis. Together, the three arms produce a caloric deficit larger than any single-agonist approach has achieved in comparable studies ^[8][11].

A 2024 review characterizes the tri-agonist mechanism as the pharmacological basis for weight reductions rivaling bariatric surgery ^[11].

Phase 1b: pharmacokinetics and first efficacy signal

The first-in-human Phase 1b trial enrolled 72 adults with type 2 diabetes and measured pharmacokinetics (how the drug moves through the body), tolerability, and early efficacy at doses from 0.5 mg to 12 mg once weekly over 12 weeks ^[4].

Key findings: retatrutide has a half-life of approximately 6 days, supporting once-weekly dosing. The highest-dose group lost a placebo-adjusted 8.96 kg (90% CI: −11.16 to −6.75 kg) over 12 weeks. Daily glucose fell by 2.8 mmol/L at 3 mg. Treatment-emergent adverse events (TEAEs) occurred in 63% of participants, mostly GI in nature. No severe hypoglycemia was recorded ^[4].

Phase 1b established the once-weekly dosing schedule and the dose escalation approach used in all subsequent trials.

Phase 2: obesity (48-week trial)

The Phase 2 obesity trial enrolled 338 adults with a BMI of 30 or above (or 27–30 with a weight-related comorbidity), without diabetes. Participants received 1, 4, 8, or 12 mg once weekly via subcutaneous injection for 48 weeks, with stepwise dose escalation ^[1].

Results at 48 weeks:

• Mean body-weight change: −24.2% at 12 mg versus −2.1% for placebo ^[1].
• Waist circumference: reduced by approximately 19.6 cm at 12 mg.
• GI adverse events: dose-related, mostly mild-to-moderate; nausea affected up to 45% at 12 mg.
• Heart rate: dose-dependent increase peaking around week 24, then partially stabilizing.
• Discontinuation due to AEs: 18% at the 12 mg dose.

A 2025 commentary on this trial characterizes the up to 24% weight loss as a step-change in the incretin-pharmacotherapy class ^[6]. A 2024 review notes that tri-agonist agents, of which retatrutide is the lead example, approach the weight-loss magnitude historically associated only with bariatric surgery ^[11].

Phase 2: type 2 diabetes (36-week trial)

The Phase 2 type 2 diabetes trial enrolled 281 adults inadequately controlled on background antidiabetic medication. Doses ranged from 0.5 to 12 mg once weekly with stepwise escalation over 36 weeks ^[2].

Results:

• HbA1c reduction at 24 weeks: −2.02% at 12 mg versus −0.01% for placebo ^[2].
• Body weight at 36 weeks: −16.94% at 12 mg versus −3.00% for placebo.
• Mild-to-moderate GI AEs in 35% of participants.
• No severe hypoglycemia, no deaths ^[2].

The glycemic and weight results in the diabetic population are consistent with — and at 12 mg largely comparable to — the obesity cohort, establishing that the weight-loss effect persists in individuals with insulin resistance.

Phase 2a: liver disease (MASLD substudy)

A dedicated Phase 2a substudy enrolled 98 participants with obesity or overweight and MASLD (metabolic dysfunction-associated steatotic liver disease — the current term for fatty liver linked to metabolic risk factors, formerly called NAFLD), with confirmed liver fat of at least 10% by MRI-PDFF (magnetic resonance imaging proton density fat fraction, a non-invasive measure of liver-fat content), without type 2 diabetes ^[5].

Results at 24 weeks:

• Relative liver-fat change at 12 mg: −82.4% versus +0.3% for placebo ^[5].
• Proportion reaching normal liver fat (<5%): 86% at 12 mg.
• Reductions sustained and deepened to 48 weeks (−86.0% at 12 mg).

These are the largest liver-fat reductions reported in an incretin-class trial. An incretin-based therapy review situates retatrutide among agents showing broad cardiometabolic benefit across MASLD and related conditions ^[9].

Phase 3: TRANSCEND-T2D-1 (first published Phase 3 result)

TRANSCEND-T2D-1 is the first Phase 3 trial to report results. It enrolled 537 adults with type 2 diabetes inadequately controlled with diet and exercise over 40 weeks ^[12].

Primary results:

• HbA1c reduction: −1.94% at 12 mg versus −0.81% for placebo ^[12].
• Body weight: −15.3% at 12 mg versus −2.6% for placebo.
• Adverse events: predominantly mild-to-moderate GI; treatment discontinuation due to AEs in 8.3% of the retatrutide arm.
• No severe hypoglycemia reported.

These Phase 3 findings are directionally consistent with Phase 2 results, providing early confirmation that the efficacy signal replicates in a larger pre-approval trial. Additional TRIUMPH trials — obesity, cardiovascular outcomes, CKD outcomes, and an active comparator versus tirzepatide — remain ongoing ^[8].

Retatrutide vs tirzepatide

A head-to-head trial of retatrutide versus tirzepatide is part of the TRIUMPH program and has not reported results as of mid-2026 ^[8]. Any comparison made before those data exist is indirect and depends on cross-trial assumptions that may not hold.

What can be said from the published record: the Phase 2 obesity trial for retatrutide (−24.2% at 12 mg/48 wk) produced numerically larger reductions than tirzepatide's SURMOUNT-1 Phase 3 results in a comparable population. A 2025 review characterizes retatrutide as achieving weight reduction exceeding tirzepatide based on currently available data, while noting the direct comparison is pending ^[8]. The 2026 multi-receptor review identifies weight regain upon discontinuation as a class-level limitation shared by current GLP-1-based therapies, underscoring that no current agent — tirzepatide or retatrutide — has demonstrated persistent weight loss after stopping ^[13].

Generic names used throughout: tirzepatide is the INN. No brand names appear on this site.